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Role of miR-15a/miR-16-1 and the TP53 axis in regu-
lating telomerase expression in chronic lymphocytic
leukemia 
Chronic lymphocytic leukemia (CLL), the most preva-
lent form of leukemia in adults in the western world, has
a highly heterogeneous clinical course, and is character-
ized by genomic instability which gives rise to several
chromosomal alterations detectable in more than 80% of
CLL cases.1 While the absence of somatic mutations in
the immunoglobulin heavy-chain gene variable region
(IGVH) and high expression of CD38 and ZAP-70 mole-
cules have been associated with aggressive CLL, the most
common chromosomal abnormality, 13q14 deletion
(13q14del), has been associated with a more indolent
form of the disease.1,2 The mechanism by which 13q14del
contributes to CLL pathogenesis and affects the outcome
of patients has not yet been elucidated.
Several studies have focused on the prognostic signifi-
cance of an interplay between telomeres and telomerase
in CLL.3-6 Telomerase is responsible for the maintenance
of telomeres, structures which cap and protect the ends
of chromosomes. Telomerase expression, up-regulated in
approximately 90% of human cancers, enables continu-
ous and uncontrolled proliferation of the malignant cells
driving tumor growth and progression.7 Catalytic protein
with telomere-specific reverse transcriptase activity
(TERT) is the rate-limiting component of the telomerase
complex, and its expression is correlated with telomerase
activity.8 We and others have shown that levels of TERT
and its activity are prognostic markers in CLL.3-6 Notably,
TERT levels were found to be lower in 13q14del CLL
than in CLL with other chromosomal abnormalities,4 but
mechanistic insight for this difference is still unclear. 
The expression of microRNA, small non-coding RNA
with regulatory functions, is frequently deregulated in
tumors.9 The microRNA cluster which encodes for miR-
15a and miR-16-1 maps within a 30-kilobase region of
loss at 13q14.10 Both these microRNA interact directly
with and inhibit the expression of the anti-apoptotic
BCL2 gene, and the loss of the miR-15a/miR-16-1 cluster
due to 13q14 deletion is the main cause of BCL2 overex-
pression in CLL.10 Nonetheless, miR-15a and miR-16-1
also directly target the tumor suppressor TP53 gene, and
their overexpression is associated with repressed TP53
expression at both mRNA and protein levels.11
Transcription of the TERT gene is the key determinant in
regulating TERT expression and telomerase activity.
TP53 is an important repressor of the promoter of TERT
gene,12 and the C-terminus of TP53 interacts with and
inhibits telomerase activity.13
This study aimed at determining miR-15a/miR16-1 lev-
els in CLL and correlating them to TP53 and TERT tran-
scripts. Since 13q14del CLL cells would lack miR-
15a/miR-16-1, and since these two microRNA repress
expression of TP53,11 we hypothesized that the
miRNA/TP53 axis modulates TERT levels, and thus the
outcome of patients with 13q14del CLL. 
Peripheral blood cells were collected from 155 CLL
patients who attended the Hematology Section, Clinical
and Experimental Medicine, University of Padua (Italy).
This study included 99 cases of CLL with the 13q14 dele-
tion as the sole chromosomal abnormality detected by
fluorescence in situ hybridization (FISH), and 56 CLL
with no chromosomal abnormalities detected by FISH
[i.e., 13q14.3, 17p13.1 (TP53), and 11q22.3 (ATM) dele-
tions, and trisomy 12]. FISH was carried out as previously
described.4 CLL cases with TP53 mutations were exclud-
ed from this study. All samples were collected at the time
of diagnosis, and all patients were untreated at the time
of sampling. TERT transcripts were quantified in all sam-
ples by real-time polymerase chain reaction, as previous-
ly described.4 The expression of TP53 transcripts was
quantified in 123 CLL by real-time polymerase chain
reaction using a TaqMan Gene Expression Assay-Human
TP53:Hs01034249_m1 kit (Life Technologies, Carlsbad,
CA, USA), following the manufacturer's instructions. The
expression of miR-15a, miR-16-1 and RNU6B, used as a
control to normalize the data, was assessed in available
RNA samples from 101 cases of CLL using a standard
TaqMan MicroRNA assay kit (Life Technologies), accord-
ing to the manufacturer's instructions. Statistical analyses
were carried out using SAS version 9.1 (SAS Institute,
Cary, NC, USA). Time from diagnosis to first treatment
was considered as a marker for time to disease progres-
sion. Informed consent was obtained according to the
Helsinki Declaration and the study was approved by the
local Ethics Committee.
As expected, both miR-15a and miR-16-1 levels were
lower in 13q14del CLL than in CLL without chromoso-
mal abnormalities [1.97 (1.12-3.34) versus 2.86 (1.90-
4.66), P=0.009 and 0.15 (0.13-0.31) versus 0.25 (0.17-
0.37), P=0.001)] (Table 1) and positive correlations were
found between miR-15a and miR-16-1 levels (rs=0.854,
P<0.0001). In agreement with the fact that overexpres-
sion of miR-15a and miR-16-1 in primary CLL cells is
associated with a decrease in TP53 levels,11 TP53 mRNA
levels were significantly higher in 13q14del CLL than in
CLL with no chromosomal abnormalities [782 (416-
1186) versus 582 (304-815) copies/105 GAPDH copies
P=0.012] (Table 1). Levels of miR-15a and miR-16-1
were inversely correlated with TP53 levels in both
13q14del (rs= -0.775, P<0.0001 and rs= -0.722, P<0.0001,
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Table 1. Clinical and biological characteristics of the patients with chronic
lymphocytic leukemia according to 13q14del status.
13q14del no FISH P-valuea
abnormalities
Clinical characteristics
Men/women 46/53 33/23 0.316
Age, mean (IQR) 70 (63-76) 68 (60/75) 0.342
Binet stage A/B/C (%) 85/11/4 79/16/5 0.331
Lymphocytes >109/L (%) 42/99 14/56 0.141
Biological characteristics of CLL
IGVH unmutated (%) 19/88 (21.6) 12/46 (26.1) 0.517
CD38 >30% (%) 9/94 (9.6) 13/50 (26.0) 0.014
miRNA-15a 72/99 29/56
Median relative levelsb (IQR)1.97 (1.12-3.34) 2.86 (1.90-4.66) 0.009
miRNA-16-1 72/99 29/56
Median relative levelsb (IQR)0.15 (0.13-0.31) 0.25 (0.17-0.37) 0.001
TP53 81/99 42/56
Median relative levelsc (IQR)782 (416-1186) 582 (304-815) 0.012
TERT 99/99 56/56
Median  relative levelsd (IQR) 55 (20-115) 73 (46-198) 0.027
aAssociations between categorical variables were analyzed by the χ2 test and the distribution
of continuous variables was compared by the Kruskal-Wallis non-parametric test. bThe relative
levels of miR-15a and miR-16-1 were determined from the miRNA/RNU6B ratio according to
the  2-ΔCt formula, where ΔCt=(CtmiRNA- CtRNU6B). cTP53 relative levels were expressed as TP53
copies/105 GAPDH copies. dTERT relative levels are expressed as TERT copies/106 GAPDH
copies.
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Figure 1. Relationship among miRNA, TP53 and TERT levels in 13q14del chronic lymphocytic leukemia. (A, B) Relationship  between TERT and TP53 levels
in: (A) 13q14del CLL, (B) CLL with no chromosomal abnormalities. (C-F) Relationship between percentage of deleted nuclei and levels of (C) miR-15a, (D) miR-
16-1, (E) TP53, (F) TERT. (G) Proposed network among miR-15a/miR-16-1, TP53, and TERT expression. Down-regulation of miR-15a/miR-16-1, due to 13q14
deletion, leads to increased TP53 levels which, in turn, down-regulate levels of TERT, the catalytic component of the telomerase complex.
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respectively; data not shown) and all CLL (rs= -0.806,
P<0.0001 and rs= -704, P<0.0001, respectively; data not
shown).
13q14del CLL expressed significantly lower levels of
TERT than CLL with normal cytogenetic profile [55 (20-
115) versus 73 (46-198) copies/106 copies GAPDH,
P=0.027] (Table 1). Of interest, TP53 levels correlated
negatively with TERT levels only in 13q14del (rs= -0.359,
P=0.002, Figure 1A), but not in CLL without chromoso-
mal abnormalities (rs= 0.111, P=0.484) (Figure 1B). The
different percentage of nuclei carrying the 13q14 deletion
may explain the variable levels of miRNA, TP53, and
TERT observed within the 13q14del CLL; indeed, the
percentage of nuclei carrying the 13q14 deletion tended
to correlate negatively with miR-15a, miR-16-1 and
TERT levels (rs= -0.324, P=0.006; rs= -0.288, P=0.016; rs=
-0.277, P=0.007, respectively) (Figure 1C-E), and positive-
ly with TP53 levels (rs=0.317, P=0.004) (Figure 1F). 
Univariate Cox analyses showed that mutated IGVH
status and low TERT levels (≤ median) were prognostic
of better disease outcome, estimated as time from diag-
nosis to first treatment, in the entire cohort of CLL, with
hazard ratios (HR) and 95 confidence intervals (95% CI)
of 3.95 (2.11-7.43) P<0.001 and 2.19 (1.21-3.97) P=0.008,
respectively, and also in the subgroup of patients with
13q14del CLL (Table 2). Of interest, cases with high TP53
expression had a better prognosis in the subgroup of
13q14del CLL (Table 2), but not in that of CLL with nor-
mal cytogenetic profile [HR 0.97 (95% CI 0.29-3.28);
P=0.973]. CD38 (>30%) was not prognostic of disease
outcome in 13q14del CLL [HR 2.28 (95% CI 0.86-6.04)
P=0.107; data not shown]. Multivariate Cox analysis
showed that within 13q14del CLL, a high TERT/low
TP53 level profile defined the subgroup of cases with the
worst prognosis (Table 2) and the values of TERT/TP53
profiles were independent of IGVH mutational status
(Table 2). 
This result, together with the finding that a negative
correlation between TP53 and TERT levels can only be
observed in 13q14del CLL but not in CLL without chro-
mosomal abnormalities, emphasizes the existence of a
network between miR-15a/miR-16-1, TP53 and TERT
within 13q14del CLL (Figure 1G).
It should be noted that miRNA expression also varied
in CLL without chromosomal aberrations; therefore,
mechanisms other than deletion of the miRNA cluster in
the 13q14 region probably contribute to regulating their
expression. It has recently been demonstrated that miR-
15a/miR16-1 and TP53 are engaged in a feedback loop in
CLL: increased levels of miR-15a/miR16-1 target and
down-regulate TP53 expression, while TP53 binds to its
specific binding sites on chromosome 13 and up-regu-
lates the expression of miR-15a/miR-16-1 in CLL with a
normal cytogenetic profile.11 As the expression of TP53 in
CLL is influenced by many factors,14 this variability may
influence levels of the miRNA, which in turn down-regu-
late TP53 expression.
Notably, in this study TP53 had prognostic value only
for 13q14del CLL. It has been advanced that CLL with a
high percentage of 13q14 deletion tend to have a worse
prognosis.15 The deletion of miR-15a and miR-16-1 and
the consequent lack of inhibition of the anti-apoptotic
BCL2 gene may partially support this trend. However,
miR-15a and miR-16-1 also target the tumor suppressor
gene TP53. Hence, the loss of the miR-15a/miR-16-1
cluster due to 13q14 deletion not only moves the balance
toward higher levels of anti-apoptotic protein, but also
toward higher levels of tumor suppressor TP53. With a
cut-off of 80% of 13q14 deleted nuclei,15 we did not find
any significant differences in disease outcome (HR 0.597;
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Table 2. Time to first treatment and hazard ratio according to IGVH status, TERT levels, and TP53 levels showing their effects on disease pro-
gression in chronic lymphocytic leukemia with 13q14 deletion.
TTFTa P-value Hazard ratio HR
months log-rank (95% CI)b P-value
(95% CI)-
IGVH status < 0.0001
IGVHmutated 211 (110;-) 1
IGVH unmutated 32 (6;157) 4.05 (1.90;8.54) 0.0003
TERT levels 0.026
TERT lowc 211 (104;-) 1
TERT highc 84 (53;157) 2.24 (1.08;4.67) 0.030
TP53 levels 0.038
TP53 lowc 96 (32;-) 2.36 (1.02;5.49)
TP53 highc 157 (149;-) 1 0.044
TERT & TP53 levels 0.012
TERT high & TP53 high 157 (153;-) 0.22 (0.06;0.83) 0.025
TERT low & TP53 low - (96;-) 0.27 (0.07;0.99) 0.047
TERT high & TP53 low 32 (5;-) 1
TERT low & TP53 high 221 (104;-) 0.29 (0.11;0.77) 0.013
TERT, TP53 levels & IGVH status < 0.0001
Other; IGVH unmutated 157 (1;157) 0.29 (0.12;0.69) 0.006
Other; IGVHmutated 221 (104;-) 0.11 (0.03;0.37) 0.0004
TERT high & TP53 low; IGVH unmutated 12 (1;32) 1
TERT low & TP53 high; IGVHmutated - (25;-) 0.38 (0.15;0.96) 0.040
For each variable, time to first treatment (TTFT) analysis was estimated using the Kaplan-Meier method and compared with the log-rank test. TERT and TP53 levels were
analyzed as dichotomous variables (cut-off:≤median or >median). Hazard ratios for each category were estimated using univariate Cox proportional hazards models. The
independent role of the TERT/TP53 level profile in predicting TTFT was tested using a Cox proporzional hazard model, and was adjusted for IGVHmutational status. cTERT
or TP53 low: ≤ median level;  TERT or TP53 high:> median level. aTTFT: time to first treatment. bCI: confidence interval.
95% CI: 0.304-1.173; P=0.135). This supports the con-
cept that the effects of deletion, rather than the percent-
age of deletion per se, influence the disease outcome. 
An interesting and intriguing result of our study is that
levels of TP53 were inversely correlated with TERT levels
only in the 13q14del CLL cases. TP53 alone may be inef-
ficient in regulating TERT, since many other factors acti-
vate or repress TERT at a transcriptional level.7 Our find-
ings suggest that TP53 plays an important role in TERT
regulation in 13q14del CLL, while in CLL with no or
other chromosomal aberrations TERT may be regulated
by other factors. 
In conclusion, collectively, these findings indicate that, in
13q14del CLL, the miR15/miR16-1 cluster and TP53 axis is
an important pathway which regulates TERT expression,
thus influencing disease outcome, and also suggest that
analysis of TERT/TP53 profiles may be useful in refining
the prognosis of patients with 13q14del CLL. 
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